| Literature DB >> 19565017 |
Toshihiko Sawada1, Tomohiro Hashimoto, Hiroaki Tokiwa, Tohru Suzuki, Hirofumi Nakano, Hideharu Ishida, Makoto Kiso, Yasuo Suzuki.
Abstract
Mutations in avian influenza A viral hemagglutinin HA1 domain may alter the binding specificity of HA for alpha-sialosaccharide receptors, shifting the virus's host range from birds to humans. The amino acid mutations can occur at the sialoside binding site, as well as the antigenic site, far from the binding site. Thus, a theoretical study involving the in silico prediction of HA-sialosaccharide binding may require quantum chemical analysis of HA1 full domain complexed with sialosides, balancing a computational cost with model size of HA1-sialoside complex. In addition, there is no insight to relationship between the model size of HA1-sialoside complex and its binding energy. In this study, H3 subtype HA1 full domains complexed with avian- and human-type Neu5Acalpha(2-3 and 2-6)Gal receptor analogs was investigated by ab initio based fragment molecular orbital (FMO) method at the level of second-order Møller-Plesset perturbation (MP2)/6-31G. Using this approach, we found avian H3 HA1 to bind to avian alpha2-3 receptor more strongly than to human alpha2-6 receptor in gas phase, by a value of 15.3-16.5 kcal/mol. This binding benefit was larger than that in the small model complex. Analysis of the interfragment interaction energies (IFIEs) between Neu5Ac-Gal receptor and amino acid residues on the full domain of H3 HA1 also confirmed the higher avian H3-avian alpha2-3 binding specificity. It was particularly important to evaluate the IFIEs of amino acid residues in a 13A radius around Neu5Ac-Gal to take account of long-range electrostatic interactions in the larger HA1-sialoside complex model. These results suggest suitable size of HA1-sialoside complex is significant to estimate HA1-sialoside binding energy and IFIE analysis with FMO method.Entities:
Keywords: FMO; Virus host range; ab initio; binding energy; interfragment interaction energy; lectin; second-order Møller–Plesset perturbation; sialosaccharide
Year: 2008 PMID: 19565017 PMCID: PMC2702072
Source DB: PubMed Journal: J Mol Genet Med ISSN: 1747-0862
Figure 1.The complexes of influenza A virus H3 HA1 domain with Neu5Ac-Gal analog for the FMO-MP2/6-31G calculations. A. The complex has the smallest receptor binding site (Sawada et al, 2006, 2008). The site has four peptides Asn96-Pro99, Gly129-Tyr161, Gly181-Val196, and Asn216-Ile232 to be total 70 amino acids. B. Binding domain in the complex consists of Arg(Ile)62-Gly263 (202 amino acids, avian H3; Arg62, human H3; Ile62), C. The complex has the full size of HA1 domain (avian H3; Ser9-Lys326, human H3; Gln1-Thr328, Sawada et al, 2007). ribbon model; HA1, red; helix, blue; sheet, CPK model; Neu5Ac-Gal analog.
Figure 2.Schematic fragmentation of H3 HA1 domain. HA1 domain was fragmented by cutting Cα-C bonds in accordance with general manner (Fedorov and Kitaura, 2006). Cα were bond detached atoms. Fragment 1, 2,…, i, i+1,…, N were treated as amino acid residue 1, 2,…, i, i+1,…, N.
Figure 3.Schematic structures of avian and human receptor Neu5Acα(2-3 and 2-6)Gal
Basic and acidic amino acid residues in the models A-C
| H3 | model | Arg | Lys | His | terminal NH3+ | Asp | Glu | ternimal COO- |
|---|---|---|---|---|---|---|---|---|
| 141 | 140, 156 | 183(E), 184(E) | Asn96, Glyl29, Glyl81, Asn216 | 158, 190 | Pro99, Tyrl61, Val 196, Ile232 | |||
| 62 | 140, 156, 176, 238, 259 | 75(E), 183(E), 184(E) | Arg62 | 68, 73, 77, 85, 101, 104, 172, 175, 241 | 82, 89, 119, 123, 158, 190 | Gly263 | ||
| 57,62 | 27, 50, 140, 156, 176, 238, 259, 264, 292, 299, 307, 310, 315, 326 | 17(E), 18(E), 56(E), 75(E), 183(E), 184(E) | Ser9 | 31, 32, 60, 68, 73, 77, 85, 191, 104, 172, 175, 241, 271, 275, 291 | 35, 41, 82, 89, 119, 123, 158, 190, 280, 325 | Lys326 | ||
| 141 | 140, 156 | 183(E), 184(E) | Asn96, Glyl29, Glyl81, Asn216 | 190 | Pro99, Tyrl61, Val 196, Ile232 | |||
| 90, 109, 141, 150, 201, 207, 208, 220, 224, 229, 255, 261 | 92 | 75(P), 183(E), 184(E) | Ile62 | 63, 68, 73, 77, 85, 101, 104, 172, 175, 241 | 82, 89, 119, 123, 190 | Gly263 | ||
| 57, 90, 109, 141, 150, 201, 207, 208, 220, 224, 229, 255, 261 | 27, 50, 92, 140, 156, 176, 238, 259, 264, 292, 299, 307, 310, 315, 326 | 17(D), 18(E), 56(E), 75(P), 183(E), 184(E) | Glnl | 2, 7, 31, 32, 60, 63, 68, 73, 77, 85, 101, 104, 172, 175, 241, 271, 275, 291 | 35, 41, 82, 89, 119, 123, 190, 280, 325 | Thr328 | ||
Sawada et al, 2006, 2008
Sawada et al, 2007
Side chain δ-guanidium on Arg and ε-ammonium on Lys are neutralized in order to compute neutral H3–sialoside complex.
There are three types of histidine. E; neutral form with NE proton. D; neutral form with ND proton. P; positive charged form with ND and NE protons.
Binding energies in kcal/mol of avian H3 with avian/human Neu5Acα(2-3/6)Gal receptors
| Entry | Model | MP2/6-31G | |
|---|---|---|---|
| 1 | Δ | 180.4 | |
| 2 | 204.5 | ||
| 3 | 200.0 | ||
| 4 | Δ | 169.0 | |
| 5 | 189.2 | ||
| 6 | 183.5 | ||
| 7 | Δ | 11.4 | |
| 8 | 15.3 | ||
| 9 | 16.5 |
These data were previously reported in Sawada et al (2008).
Binding energies in kcal/mol of human and avian Gln226Leu H3s with human Neu5Acα(2-6)Gal receptors
| Entry | H3 | Model | Δ |
|---|---|---|---|
| 1 | Human | 154.3 | |
| 2 | 190.2 | ||
| 3 | 203.1 | ||
| 4 | Avian Gln226Leu | 157.6 | |
| 5 | 177.4 | ||
| 6 | 172.3 |
These data were previously reported in Sawada et al (2008).
The sums of IFIEs between human Neu5Acα(2-6)Gal with amino acid residues on avian and human H3 in the models A and B at the FMO-MP2/6-31G level
| Entry | amino acid residues | sum of IFIEs (kcal/mol) | ||
|---|---|---|---|---|
| avian H3 | human H3 | |||
| model | substituted residues (non-charge) | 70.6 | 72.3 | |
| substituted residues (charge) | -16.7 | 1.2 | ||
| Arg, Lys, His(P), Asp, Glu | 71.2 | 40.2 | ||
| terminal residues | 2.6 | 0.3 | ||
| others | 108.1 | 105.9 | ||
| total | 235.8 | 219.9 | ||
| model | model | |||
| substituted residues (non-charge) | 69.2(-1.4) | 70.3(-2.0) | ||
| substituted residues (charge) | -16.8(-0.1) | 1.2(0.0) | ||
| Arg, Lys, His(P), Asp, Glu | 156.8(85.6) | 158.3(118.1) | ||
| terminal residues | 6.3(3.7) | 4.4(4.1) | ||
| others | 79.3(-28.8) | 73.7(-32.2) | ||
| total | 294.8(59.0) | 307.9(88.0) | ||
| model | ||||
| substituted residues (non-charge) | -0.2 | -0.3 | ||
| substituted residues (charge) | 0.4 | -14.6 | ||
| Arg, Lys, His(P), Asp, Glu | -67.4 | -62.5 | ||
| terminal residues | 4.2 | 4.1 | ||
| others | 3.8 | 1.5 | ||
| total | -59.2 | -71.8 | ||
| model | 235.6 | 236.1 | ||
amino acid positions are 137, 144, 145, 160, 182, 193, 226, 227, and 228
amino acid position is 158
their form are shown in table 1; model A
N- and C-terminal residues are charged +1 and −1, respectively (table 1; model A)
their form are shown in table 1; model B
the residues do not charged because they are parts of peptide chain in model B.
amino acid position is 102
amino acid positions are 63 and 92
N- and C-terminal residues are 62 and 263 as shown in table 1; model B
values in parenthesis are given by [model A]-[model A range in model B]
Figure 4.Sequence alignments of avian and human H3 HA1 in the model complexes A, B, and C: Yellow; non-matching residue, green; weak matching residues, light blue; strong matching residue, brown; smallest binding site in the model A, purple; difference in the model B and C.
Sum of IFIEs between avian/human Neu5Acα(2-3 and 2-6)Gal and amino acid residues on avian H3 models B and C at the FMO-MP2/6-31G level
| Entry H3 | model | amino acid residues | sum of IFIEs (kcal/mol) | Δ | |
|---|---|---|---|---|---|
| avian α2-3 | human α2-6 | ||||
| model | 317.5 | 294.8 | 22.7 | ||
| 13Å | 358.4 | 337.2 | 21.2 | ||
| 13Å + charged residues | 260.4 | 237.0 | 23.4 | ||
| all (Arg62-Gly263) | 258.6 | 235.6 | 23.0 | ||
| model A | 316.4 | 293.7 | 22.7 | ||
| 13Å | 357.3 | 336.1 | 21.2 | ||
| 13Å + charged residues | 251.9 | 227.8 | 24.1 | ||
| model | 253.7 | 230.7 | 23.0 | ||
| all (Ser9-Lys326) | 252.5 | 228.7 | 23.8 | ||
Δ represents [sum of IFIEs between avian α2-3 and amino acids]-[sum of IFIEs between human α2-6 and amino acids].
model A consists of 70 amino acid residues (Asn96-Pro99, Gly129-Tyr161, Gly181-Val196, Asn216-Ile232, Figure 5)
Amino acid residues within 13Å radius around Neu5Ac-Gal are Pro74, Asn96-Pro99, Val130-Ser157, Tyr161, Leu164, Gly181-Gln197, Asn216-Pro221, Val223-Ile232, Asn250-Ala253, and Arg255.
Charged residues are listed in table 1
Sum of IFIEs between human Neu5Acα(2-6)Gal and amino acid residues on human Leu226 and avian Gln226Leu H3 models B and C at the FMO-MP2/6-31G level
| Entry H3 | model | amino acid residues | human α2-6 |
|---|---|---|---|
| model | 307.9 | ||
| 13Å | 331.2 | ||
| 13Å + charged residues | 238.9 | ||
| all(Ile62-Gly263) | 236.1 | ||
| model | 308.5 | ||
| 13Å | 332.0 | ||
| 13Å + charged residues | 248.2 | ||
| model | 254.8 | ||
| Ser9-Lys326 | 255.0 | ||
| all(Gln1-Thr328) | 248.1 | ||
| model | 282.4 | ||
| 13Å | 324.8 | ||
| 13Å + charged residues | 224.2 | ||
| all(Arg62-Gly263) | 222.4 | ||
| model | 281.2 | ||
| 13Å | 323.7 | ||
| 13Å + charged residues | 215.6 | ||
| Arg62-Gly263 | 217.5 | ||
| all(Ser9-Lys326) | 216.1 |